Gunderson Dettmer represented client Remix Therapeutics, a Massachusetts-based biotech company, in its $70 million Series B financing which included participation from Surveyor, Foresite Capital, Atlas Ventures, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital. Remix Therapeutics focuses on developing novel small molecule therapies designed to reprogram RNA processing and treat diseases in new ways. The new capital will enable the company to support development of its REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

In the announcement of the transaction, Co-Founder and CEO of Remix Therapeutics Peter Smith, Ph.D. said, “We are pleased to announce this Series B financing that reflects the significant progress we have made to advance our novel platform and programs modulating RNA processing. With the support of our new and existing investors, we will continue on our path to address disease drivers at their origin.”

The Gunderson deal team was led by Tim Ehrlich and included David Horne, Graham Rogers, Alexandra Noymer, Aliya Sanders and Carson Heyer.